Amanda H Corbett

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi request reprint Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline
    Amanda H Corbett
    School of Pharmacy, The University of North Carolina Hospitals, Chapel Hill 27514, USA
    Curr Opin Investig Drugs 3:384-90. 2002
  2. pmc Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children
    Amanda H Corbett
    University of North Carolina Schools of Pharmacy, Medicine and Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Antivir Ther 15:83-90. 2010
  3. pmc Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir
    Amanda H Corbett
    School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Antimicrob Agents Chemother 50:2756-61. 2006
  4. pmc Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis
    Julie B Dumond
    School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina, USA
    AIDS 21:1899-907. 2007
  5. ncbi request reprint The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir
    Amanda H Corbett
    Schools of Pharmacy and Medicine, University of North Carolina Center for AIDS Research, University of North Carolina at Chapel Hill, 27599, USA
    J Acquir Immune Defic Syndr 36:921-8. 2004
  6. pmc Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicity
    Marypeace McRae
    University of North Carolina at Chapel Hill, 27599 7360, USA
    Pharmacotherapy 30:17-24. 2010
  7. ncbi request reprint Kaletra (lopinavir/ritonavir)
    Amanda H Corbett
    School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7360, USA
    Ann Pharmacother 36:1193-203. 2002
  8. pmc Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians
    Kevin C Brown
    University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, 3202 Kerr Hall, Chapel Hill, NC 27599 7569, USA
    Pharmacogenomics 13:113-21. 2012
  9. ncbi request reprint Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry
    Byung Hwa Jung
    Clinical Pharmacology and Analytical Chemistry Core, Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Biomed Chromatogr 21:1095-104. 2007
  10. pmc Self-report of current and prior antiretroviral drug use in comparison to the medical record among HIV-infected patients receiving primary HIV care
    Emily Suzanne Brouwer
    Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA
    Pharmacoepidemiol Drug Saf 20:432-9. 2011

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline
    Amanda H Corbett
    School of Pharmacy, The University of North Carolina Hospitals, Chapel Hill 27514, USA
    Curr Opin Investig Drugs 3:384-90. 2002
    ..In September 2000 and January 2001, Merrill Lynch predicted a 2002 launch, with sales of pounds sterling 50 million in 2002, rising to pounds sterling 150 million in 2004...
  2. pmc Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children
    Amanda H Corbett
    University of North Carolina Schools of Pharmacy, Medicine and Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Antivir Ther 15:83-90. 2010
    ....
  3. pmc Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir
    Amanda H Corbett
    School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Antimicrob Agents Chemother 50:2756-61. 2006
    ..67 [0.54 to 0.83] and 0.77 [0.59 to 0.99], respectively) compared to simultaneous administration. Additional investigations are warranted to determine the optimal dosing of FPV with LPV/RTV...
  4. pmc Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis
    Julie B Dumond
    School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina, USA
    AIDS 21:1899-907. 2007
    ..To describe first dose and steady state antiretroviral drug exposure in the female genital tract...
  5. ncbi request reprint The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir
    Amanda H Corbett
    Schools of Pharmacy and Medicine, University of North Carolina Center for AIDS Research, University of North Carolina at Chapel Hill, 27599, USA
    J Acquir Immune Defic Syndr 36:921-8. 2004
    ..These data suggest that amprenavir/saquinavir/ritonavir may be a viable salvage regimen in heavily PI-experienced individuals. New formulations of amprenavir and saquinavir may simplify this regimen...
  6. pmc Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicity
    Marypeace McRae
    University of North Carolina at Chapel Hill, 27599 7360, USA
    Pharmacotherapy 30:17-24. 2010
    ....
  7. ncbi request reprint Kaletra (lopinavir/ritonavir)
    Amanda H Corbett
    School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7360, USA
    Ann Pharmacother 36:1193-203. 2002
    ..To review the pharmacology, virology, pharmacokinetics, efficacy, safety, and clinical use of lopinavir/ritonavir (Kaletra, Abbott Laboratories)...
  8. pmc Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians
    Kevin C Brown
    University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, 3202 Kerr Hall, Chapel Hill, NC 27599 7569, USA
    Pharmacogenomics 13:113-21. 2012
    ..Genetic polymorphisms have the potential to influence drug metabolism and vary among ethnic groups. This study evaluated the correlation of genetic polymorphisms with nevirapine pharmacokinetics exposure in Malawians...
  9. ncbi request reprint Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry
    Byung Hwa Jung
    Clinical Pharmacology and Analytical Chemistry Core, Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Biomed Chromatogr 21:1095-104. 2007
    ..This method is very effective for quantifying and screening antiretroviral drugs in clinical samples with limited (50 microL) volumes...
  10. pmc Self-report of current and prior antiretroviral drug use in comparison to the medical record among HIV-infected patients receiving primary HIV care
    Emily Suzanne Brouwer
    Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA
    Pharmacoepidemiol Drug Saf 20:432-9. 2011
    ..In this study we assessed the ability of HIV-infected patients receiving care in a university infectious diseases clinic to accurately recall current and past ARVs...
  11. doi request reprint Implementation of targeted interventions to decrease antiretroviral-related errors in hospitalized patients
    Lindsay M Daniels
    Department ofPharmacy, University of North Carolina Hospitals, Chapel Hill, NC 27514, USA
    Am J Health Syst Pharm 69:422-30. 2012
    ..The implementation and effectiveness of targeted interventions aimed at decreasing the frequency of antiretroviral-related errors in hospitalized patients with human immunodeficiency virus (HIV) are described...
  12. doi request reprint Frequency of HIV-related medication errors and associated risk factors in hospitalized patients
    Sonak D Pastakia
    Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Purdue University, Indianapolis, IN 46202, USA
    Ann Pharmacother 42:491-7. 2008
    ..Retrospective studies of hospitalized HIV-infected patients have noted a high occurrence of drug-related errors, ranging from 5% to 30%...
  13. ncbi request reprint Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults
    Mina C Hosseinipour
    University of North Carolina Project, Lilongwe Malawi
    AIDS 21:59-64. 2007
    ..The Malawian antiretroviral program uses generic Triomune (stavudine, lamivudine, and nevirapine)...
  14. ncbi request reprint Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women
    Sherene S Min
    Schools of Medicine, University of North Carolina, Chapel Hill 27599 7360, USA
    J Acquir Immune Defic Syndr 37:1577-80. 2004
    ..Of 8 ARVs, CVF concentrations ranged from <10% to >100% of BP concentrations. These large differences in CVF penetration suggest that further research into ARV pharmacokinetics and drug efficacy in the FGT is necessary...